Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease
Standard
Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease. / Van de Veire, Sara; Stalmans, Ingeborg; Heindryckx, Femke; Oura, Hajimu; Tijeras-Raballand, Annemilaï; Schmidt, Thomas; Loges, Sonja; Albrecht, Imke; Jonckx, Bart; Vinckier, Stefan; Van Steenkiste, Christophe; Tugues, Sònia; Rolny, Charlotte; De Mol, Maria; Dettori, Daniela; Hainaud, Patricia; Coenegrachts, Lieve; Contreres, Jean-Olivier; Van Bergen, Tine; Cuervo, Henar; Xiao, Wei-Hong; Le Henaff, Carole; Buysschaert, Ian; Kharabi Masouleh, Behzad; Geerts, Anja; Schomber, Tibor; Bonnin, Philippe; Lambert, Vincent; Haustraete, Jurgen; Zacchigna, Serena; Rakic, Jean-Marie; Jiménez, Wladimiro; Noël, Agnes; Giacca, Mauro; Colle, Isabelle; Foidart, Jean-Michel; Tobelem, Gerard; Morales-Ruiz, Manuel; Vilar, José; Maxwell, Patrick; Vinores, Stanley A; Carmeliet, Geert; Dewerchin, Mieke; Claesson-Welsh, Lena; Dupuy, Evelyne; Van Vlierberghe, Hans; Christofori, Gerhard; Mazzone, Massimiliano; Detmar, Michael; Collen, Désiré; Carmeliet, Peter.
in: CELL, Jahrgang 141, Nr. 1, 02.04.2010, S. 178-90.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Further pharmacological and genetic evidence for the efficacy of PlGF inhibition in cancer and eye disease
AU - Van de Veire, Sara
AU - Stalmans, Ingeborg
AU - Heindryckx, Femke
AU - Oura, Hajimu
AU - Tijeras-Raballand, Annemilaï
AU - Schmidt, Thomas
AU - Loges, Sonja
AU - Albrecht, Imke
AU - Jonckx, Bart
AU - Vinckier, Stefan
AU - Van Steenkiste, Christophe
AU - Tugues, Sònia
AU - Rolny, Charlotte
AU - De Mol, Maria
AU - Dettori, Daniela
AU - Hainaud, Patricia
AU - Coenegrachts, Lieve
AU - Contreres, Jean-Olivier
AU - Van Bergen, Tine
AU - Cuervo, Henar
AU - Xiao, Wei-Hong
AU - Le Henaff, Carole
AU - Buysschaert, Ian
AU - Kharabi Masouleh, Behzad
AU - Geerts, Anja
AU - Schomber, Tibor
AU - Bonnin, Philippe
AU - Lambert, Vincent
AU - Haustraete, Jurgen
AU - Zacchigna, Serena
AU - Rakic, Jean-Marie
AU - Jiménez, Wladimiro
AU - Noël, Agnes
AU - Giacca, Mauro
AU - Colle, Isabelle
AU - Foidart, Jean-Michel
AU - Tobelem, Gerard
AU - Morales-Ruiz, Manuel
AU - Vilar, José
AU - Maxwell, Patrick
AU - Vinores, Stanley A
AU - Carmeliet, Geert
AU - Dewerchin, Mieke
AU - Claesson-Welsh, Lena
AU - Dupuy, Evelyne
AU - Van Vlierberghe, Hans
AU - Christofori, Gerhard
AU - Mazzone, Massimiliano
AU - Detmar, Michael
AU - Collen, Désiré
AU - Carmeliet, Peter
N1 - Copyright 2010 Elsevier Inc. All rights reserved.
PY - 2010/4/2
Y1 - 2010/4/2
N2 - Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.
AB - Our findings that PlGF is a cancer target and anti-PlGF is useful for anticancer treatment have been challenged by Bais et al. Here we take advantage of carcinogen-induced and transgenic tumor models as well as ocular neovascularization to report further evidence in support of our original findings of PlGF as a promising target for anticancer therapies. We present evidence for the efficacy of additional anti-PlGF antibodies and their ability to phenocopy genetic deficiency or silencing of PlGF in cancer and ocular disease but also show that not all anti-PlGF antibodies are effective. We also provide additional evidence for the specificity of our anti-PlGF antibody and experiments to suggest that anti-PlGF treatment will not be effective for all tumors and why. Further, we show that PlGF blockage inhibits vessel abnormalization rather than density in certain tumors while enhancing VEGF-targeted inhibition in ocular disease. Our findings warrant further testing of anti-PlGF therapies.
KW - Angiogenesis Inhibitors
KW - Animals
KW - Antibodies, Monoclonal
KW - Carcinoma, Hepatocellular
KW - Choroid
KW - Disease Models, Animal
KW - Eye Diseases
KW - Humans
KW - Liver Neoplasms, Experimental
KW - Mice
KW - Mice, Inbred BALB C
KW - Mice, Inbred C57BL
KW - Mice, Transgenic
KW - Neovascularization, Physiologic
KW - Papilloma
KW - Placenta Growth Factor
KW - Pregnancy Proteins
KW - Skin Neoplasms
KW - Journal Article
KW - Research Support, N.I.H., Extramural
KW - Research Support, Non-U.S. Gov't
U2 - 10.1016/j.cell.2010.02.039
DO - 10.1016/j.cell.2010.02.039
M3 - SCORING: Journal article
C2 - 20371353
VL - 141
SP - 178
EP - 190
JO - CELL
JF - CELL
SN - 0092-8674
IS - 1
ER -